This drug can boost radiation therapy against cancer cells, a new clinical trial finds. In the test, the researchers used a radiotherapy-boosting drug.
To date, cancer is considered to be one of the leading causes of deaths in the United States. The country will see 1,735,350 new cancer cases by the end of this year and 609,640 of them will die.
Radiation therapy is a common treatment used to kill cancer cells and stop them from growing. Sometimes it used together with chemotherapy.
The researchers conducted a test to boost the radiation therapy’s strength to fight against cancer cells. Scientists tested a new drug called 5-iodo-2-pyrimidinone-2′-deoxribose (IpdR) combined with radiation therapy in cancer patients.
The findings were presented in Ireland at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Dr. Timothy Kinsella, from the Department of Radiation Oncology at the Warren Alpert Medical School of Brown University and Rhode Island Hospital.
Based on the clinical trial, doctors said that before coming for radiation treatment, patients took IPdR at home and their IudR’s level – a compound worked very well to improve the effectiveness of radiotherapy – in bloodstream became strong enough to enable radiation kill cancer cells.
“In newly diagnosed patients, it could be that we can safely use a higher dose and have a bigger effect on tumors,” Dr. Timothy Kinsella suggests.
“This trial is the first to test it out in patients while they are receiving radiation therapy, and the results suggest that it’s safe with minimal side effects.”